VOA慢速英语2021 美国诺瓦瓦克斯的新冠疫苗有效率达90%（在线收听）

American vaccine maker Novavax says a large study found its COVID-19 shot is 90 percent effective against the coronavirus and several virus variants.

美国疫苗制造商诺瓦瓦克斯公司表示，一项大型研究发现其新冠肺炎疫苗对新冠病毒及几种病毒变种的有效率达90%。

The results, announced Monday, were based on late-stage trials involving nearly 30,000 volunteers in the United States and Mexico.

周一宣布的这个结果是基于涉及美国和墨西哥近3万名志愿者的后期阶段试验。

Novavax said the two-shot vaccine was about 90 percent effective and data showed it was safe. The company says it plans to seek emergency approval for the vaccine in the U.S., Europe and elsewhere by the end of September.

诺瓦瓦克斯公司表示，这种两针疫苗有效率大约为90%，并且数据表明它很安全。该公司称计划寻求于9月底之前在美国、欧洲和其它地方获得该疫苗的紧急批准。

It estimates it would then be able to start producing up to 100 million injections a month. The company says it aims to supply 110 million doses to the U.S. over the next year and a total of 1.1 billion doses to developing countries.

据估计届时该公司每个月可以生产多达1亿剂疫苗。该公司称其目标是在未来一年向美国提供1.1亿剂疫苗，以及向发展中国家一共提供11亿剂疫苗。

The vaccine -- which is easy to store and transport -- is expected to play an important part in increasing the availability of shots in the developing world.

这种便于运输和储藏的疫苗有望在提高发展中国家的疫苗供给方面发挥重要作用。

"Many of our first doses will go to ... low- and middle-income countries, and that was the goal to begin with," Novavax Chief Executive Stanley Erck told The Associated Press.

诺瓦瓦克斯公司首席执行官斯坦利·厄克告诉美联社：“我们第一批疫苗中的大多数将运到中低收入国家，这就是我们最开始的目标。”

While more than half of the U.S. population has had at least one vaccine injection, less than 1 percent of people in the developing world have had one shot, researcher Our World In Data reports.

研究机构“ 以数据看世界”报告称，虽然美国超过一半人口至少注射过一剂疫苗，发展中国家只有不到1%的人口注射过一剂疫苗。

The Pfizer, Moderna and Johnson & Johnson vaccines have already been approved for emergency use in the U.S. and Europe. Europe also uses a vaccine developed by AstraZeneca.

辉瑞、莫德纳和强生公司的疫苗已经获准在美国和欧洲的紧急使用。欧洲还使用阿斯利康开发的疫苗。

Novavax's study involved nearly 30,000 people ages 18 and up. Two-thirds of subjects received two injections of the vaccine, three weeks apart, with the rest receiving an inactive substance or placebo.

诺瓦瓦克斯公司的研究涉及了3万名年龄不小于18岁的人口。其中三分之二的受试者间隔3周接种了两剂疫苗。其它人则接种了非活性物质或安慰剂。

There were 77 cases of COVID-19 -- 14 in the group that got the vaccine and the rest in volunteers who received the placebo. None of the people in the vaccine group experienced moderate or severe disease.

这项试验中有77名新冠肺炎病例，其中14名接种过疫苗，其余的是接种过安慰剂的志愿者。疫苗组中没有人经历中度或重度疾病。

The vaccine was similarly effective against several variants. One of the variants first appeared in Britain and is also found in the U.S. It has especially been affecting high-risk populations, including older people and those with other health problems.

该疫苗对几种变体同样有效。其中一种变体首先出现在英国，并且也在美国被发现。它尤其影响到包括老年人和存在健康问题的高危人群。

Only minor side effects were reported in people taking part in the study, such as head and muscle aches, tiredness and pain at the injection site. The company said there were no reports of unusual blood clots or heart problems.

参与这项研究的受试者只报告了轻微的副作用，例如头部和肌肉疼痛，注射部位的疲劳和疼痛。该公司表示没有血栓或心脏问题的报告。

Novavax reported its results in a news release. It said it plans to publish the findings in a medical publication to be examined by independent experts.

诺瓦瓦克斯在新闻稿中报告了这一结果。它称其计划在医学期刊上公布研究结果供独立专家审查。